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RecentstudieshavehighlightedtheAT1receptorasapotentialtherapeutictargetinbreastcancer,whiletheroleoftheAT2subtype
in this disease has remained largely neglected. The present study describes the generation and characterization of a new cellular
model of human invasive breast cancer cells (D3H2LN-AT2) stably expressing high levels of Flag-tagged human AT2 receptor
(Flag-hAT2). These cells exhibit high-aﬃnity binding sites for AngII, and total binding can be displaced by the AT2-selective
antagonist PD123319 but not by the AT1-selective antagonist losartan. Of interest, high levels of expression of luciferase and green
ﬂuorescent protein make these cells suitable for bioluminescence and ﬂuorescence studies in vitro and in vivo. We provide here a
novel tool to investigate the AT2 receptor functions in breast cancer cells, independently of AT1 receptor activation.
1.Introduction
Angiotensin II (AngII) is the biologically active peptide
of the renin-angiotensin system, a well-known regulator
of cardiovascular homeostasis and brain functions [1, 2].
Over the past ten years, a large number of studies have
unraveledanadditionalrolefortherenin-angiotensinsystem
in proliferative pathologies such as hyperplasia and cancer
[3–8]. AngII binds to two major subtypes of receptors,
namely, AT1 and AT2. It is generally admitted that AT1
receptor activation is responsible for most of the reported
eﬀects of AngII, whereas the AT2 receptor behaves as a
negative regulator of AT1 signaling pathways [9–11]. Indeed,
functional negative crosstalk between AT1 and AT2 receptors
has been largely described in several physiopathological
conditions including hypertension [1, 10, 11]. Activation of
the AT1 receptor triggers a large number of intracellular
kinases leading to modulation of cell proliferation, migra-
tion, and inﬂammation, three processes closely associated
with tumor progression. Accordingly, several groups have
shown that blocking AT1 receptors using speciﬁc receptor
antagonists (ARBs) is eﬀective in reducing tumor growth
and metastasis in preclinical models [12–16]. Studies using
knockout animals have further pointed out a role for
stromal AT1 receptors from the host in tumor-associated
macrophages inﬁltration and in cancer-related angiogenesis
[17, 18].
Ar e c e n ts t u d y[ 19] showing a dramatic overexpression
of AT1 receptors in a subpopulation of invasive breast
tumors has highlighted the potential use of ARBs as novel
therapeutic agents against breast cancer. Indeed, it has been
shown that losartan, an AT1 receptor blocker, was able to
inhibit breast tumor growth and invasion, suggesting that
eﬀective treatments for breast cancer may be developed
using drugs already used in clinics with few side eﬀects.
These exciting ﬁndings have, however, been challenged by
a recent meta-analysis that suggested that ARBs medication
may be associated with increased risk of cancer [20]. These2 International Journal of Peptides
provocative results have not been further validated by other
groups, which rather found no eﬀect of ARBs related to the
risk of cancer [21, 22]. Nevertheless, the beneﬁcial eﬀects of
angiotensinreceptorsblockadeincancerstillremainamatter
of debate and need to be better explored, possibly with the
use of new models.
To date, most studies have mainly focused on the role
of the AT1 receptor in cancer, while the role of the AT2
subtype has been largely neglected. Discrepancies in meta-
analysis studies might reﬂect variable levels of expression of
AT2 receptors in diﬀerent tumors. It is important to keep
in mind that antagonizing the AT1 receptor by ARBs leaves
the AT2 receptor fully available for activation by local AngII.
Thus, it is essential to determine whether the AT2 receptor
antagonizes, or mimics, the eﬀects of the AT1 subtype on
cancer cell proliferation and invasion.
Recent studies examining the eﬀects of AT2 receptors
in cancer have remained controversial. Expression of AT2
receptors from either the tumor or stroma has been shown
to attenuate the growth of pancreatic carcinoma [23], lung
adenocarcinoma [24], and pheochromocytoma [25]. In
contrast, other studies indicate that AT2 receptor expression
associates with poor prognosis of astrocytomas [26] and that
its deletion or blockade delays tumor vascularization and
progression [27]. Still little is known about the eﬀects of AT2
receptors in breast cancer. Expression of AT2 receptors in
luminal epithelial cells of the normal breast has been shown
to be signiﬁcantly increased in breast hyperplasia and carci-
nomas [28]. AT2 may thus represent a new therapeutic target
against breast cancer, and elucidating the functional role of
these receptors in breast cancer is of major importance.
The aim of the present study was to provide a cellular
model for proper investigation of the eﬀects of the AT2
receptors in breast cancer progression.
2.MaterialsandMethods
2.1. Breast Cancer Cell Line. The D3H2LN cancer cell line
(obtained from Caliper’s) is a luciferase-expressing cell line
that was derived from a spontaneous lymph node metastasis
of MDA-MB-231 human breast adenocarcinoma cells [29].
D3H2LN cells were grown in DMEM 4.5g/L glucose supple-
mented with 10% fetal calf serum (FCS), 1% nonessential
amino acids, and 1% penicillin streptavidin and were main-
tained at 37◦Ci na5 %C O 2 atmosphere.
2.2. Lentiviral Vector Construct. The TRIPΔU3-EF1α-Flag-
hAT2-IRES-GFP lentiviral vector (Figure 1) was constructed
from a modiﬁed TRIP lentiviral vector [30, 31] by inserting
the entire coding sequence of Flag-tagged human AT2 recep-
tor (Flag-hAT2) between BamHI and XhoI restrictions sites
upstream of the internal ribosomal entry site (IRES) GFP
cassette. The human Flag-hAT2 sequence was ampliﬁed by
PCR using the plasmid pBC-SF containing Flag-hAT2 cDNA
(a generous gift of Dr. Laurent Daviet), the forward primer
5 -GCCGGATCCATGAAGACGATCATCGCCCTGAGC-3 
containing the Flag initiating codon, and the reverse primer
5 -CGCTCGAGTTAAGACACAAAGGTCTCCATTTC-3 
containing the stop codon of human AT2.
2.3. Lentiviral Production and Transduction. Production of
infectious recombinant lentiviruses was performed by tran-
sient transfection of 293T cells as described in [31]. For
infections, 3 × 105 D3H2LN cells in 35mm dishes were
transducedwith5μg/mLofviralp24(HIV-1capsidprotein).
48h later, cells were washed, and fresh medium was added.
The resulting stable cell line D3H2LN-AT2 was grown in
complete medium as described above for parental D3H2LN.
2.4. FACS Analysis. For FACS analysis, cells were detached
with PBS-EDTA 1mM, and 106 cells were ﬁxed in parafor-
maldehyde 4% for 10min. After 3 washes in PBS, GFP-posi-
tive cells were analyzed on FC-500 FACSCalibur ﬂow cytom-
eter using Cytomics RXP software.
2.5. Immunoprecipitation and Western Blotting. Cells were
lysed one hour in ice with RIPA buﬀer containing 50mM
Tris pH7.5, 100mM NaCl, 50mM Na Fluoride, 0.1% SDS,
0.5% Na deoxycholate, and 1% Triton X-100 and extem-
poraneously supplemented by protease inhibitors (1mM
PMSF, 1μg/mL aprotinin, 5μg/mL leupeptin, and 1μg/mL
pepstatin). The cell lysate was directly used for Western
blotting or incubated with 2μg of anti-Flag-M2 anti-
body (Sigma) overnight with rotation at 4◦Cf o rF l a g -
AT2 immunoprecipitation. Protein G sepharose beads (50%
slurry,Roche)werethenaddedforanadditionalhourat4◦C.
The immunocomplexes were washed three times with lysis
buﬀerandelutedinLaemmli’ssamplebuﬀercontainingurea
6M.
After one hour denaturation at 60◦C, proteins and
immunocomplexes were resolved on 10% SDS-PAGE and
transferred to PVDF membranes. Flag-hAT2 expression
was revealed using Flag-M2-HRP antibodies and enhanced
chemiluminescence (ECL+, GE Healthcare).
2.6. Competition Binding Assays. D3H2LN-AT2 cells (3 ×
105 cells/well) were transferred to 12-well culture plates
24h before binding assays. One day after plating, cells were
washed brieﬂy in 25mM Tris-HCl buﬀer, pH 7.4 containing
140mM NaCl, 5mM MgCl2, and 0.1% BSA. Binding
experiments were performed at 4◦C to avoid any functional
interference such as receptor activation, phosphorylation, or
internalization. Binding was initiated by the addition of 3H-
AngII (4pM) and increasing concentrations of nonradioac-
tive AngII (10−11 Mt o1 0 −6 M) as competitor, in a 500μL
volume of binding buﬀer comprising 25mM Tris-HCl, pH
7.4, 5mM MgCl2, 0.1% BSA, and 100mg/mL bacitracin.
Selective AT1 or AT2 receptor antagonists, losartan (Galena),
and PD123319 (Sigma), respectively, were used at 10−6M.
3. Results and Discussion
The aim of this study was to generate a useful cellular model
for studying the role of AT2 receptors in breast cancer. To
this end, we constructed and characterized a human breast
cancercelllinestablyexpressinghighamountsofhumanAT2
receptors at the plasma membrane. As a recipient for AT2
receptor expression, we chose the highly aggressive D3H2LNInternational Journal of Peptides 3
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Figure 2: Validation of lentiviral vector transduction and expression in D3H2LN cell lines. (a) Flow cytometer analysis of GFP-positive
cells. Grey-ﬁlled area represents noninfected parental D3H2LN cells (Ctrl), and white area represents infected D3H2LN-AT2 (AT2) cells.
(b) Biochemical validation of Flag-AT2 expression by Western blotting (anti-Flag-HRP) in total cell lysate (left panel) or in anti-Flag
immunoprecipitate fraction (right panel).
subline derived from the well-known metastatic and triple-
negative breast cancer cells MDA-MB-231 [29]. D3H2LN
cells are of particular interest for the study of breast cancer
cell progression both in vitro and in vivo since they are
highly invasive and metastatic. After intracardiac injection
into nude mice, these cells rapidly disseminate and colonize
distant organs including the brain, the lungs, and the bones
[29] which are the major sites of metastasis in human breast
cancer.Inaddition,D3H2LNcellsconstitutivelyexpresshigh
levels of ﬁreﬂy luciferase, which will be most convenient for
future in vivo bioluminescence analysis of tumor progression
and metastatic dissemination in response to AT2 receptor
activation.
Preliminary experiments indicated that D3H2LN cells
express very low levels of endogenous AT2 receptor tran-
scripts as assessed by RT-PCR (data not shown) which was
a prerequisite for our study. We thus designed a human
AT2 receptor-containing expression vector with the objective
to reach high levels of expression of the AT2 receptor and
easy detection of the receptor at the cell membrane. First,
to facilitate AT2 receptor detection, we used a Flag-tagged
human AT2 receptor (Flag-hAT2), which can be revealed by
immunoﬂuorescence and immunoprecipitation using anti-
Flag antibodies. We reasoned that by tagging the receptor
at the extracellular N-terminus, we would also be able
to easily detect its expression at the plasma membrane.
To fulﬁll the other criteria and maximize the expression
eﬃciency, the Flag-hAT2 receptor sequence was cloned into
a modiﬁed TRIP lentiviral vector containing IRES-GFP
(Figure 1). This lentiviral vector is of great interest since
it allows high levels of AT2 receptor expression, together
with concomitant expression of the green ﬂuorescent protein
(GFP) that will serve as a positive control for infection
eﬃciency. GFP expression will also be a valuable tool for the
sensitive detection of the infected cells by FACS and immu-
noﬂuorescence studies.
Lentiviral particles containing Flag-hAT2 were thus
produced and used to transduce D3H2LN cells for 48h.
Stably infected cells maintained in culture were thereafter
designated “D3H2LN-AT2” cells and further characterized.
Transduction eﬃciency was evaluated by ﬂow cytometry
measuring GFP-positive cells. As shown in Figure 2(a),
99.5% of the cells transduced with the AT2 lentiviral vector
were positive for GFP expression, indicating that virtually
all infected cells had incorporated the construct. We then
evaluated whether D3H2LN cells also expressed detectable
amounts of the AT2 receptor. To this end, we performed
Western blotting and immunoprecipitation analyses using
anti-Flag antibodies. As shown in Figure 2(b) (left panel),
anti-Flag-HRP antibodies revealed a major polypeptide at
45KDa corresponding to the molecular weight of unglyco-
sylated Flag-hAT2 receptor [32], in D3H2LN-AT2 but not
in parental D3H2LN cells. Additional polypeptides of higher
molecular weights (80 and 110KDa) immunoprecipitated
from D3H2LN-AT2 cells (Figure 2(b), right panel) might
illustrate receptor dimerization or the presence of diﬀerent
glycosylated forms of the AT2 receptor [33].
In conclusion, in the present study, we successfully
isolated a stable cell line (D3H2LN-AT2) constitutively
expressing the Flag-tagged human AT2 receptor and con-
comitantly the GFP. To note, these cells remained stable in





Figure 3: Morphological aspect of parental D3H2LN cells (Ctrl)
or D3H2LN-AT2 cells (AT2). Pictures were taken under the micro-
scopeat ×100(upperpanel)and ×400(lowerpanel)magniﬁcation.
To further characterize the D3H2LN-AT2 cells, culture
dishes were placed under a phase contrast microscope,
and pictures were taken at low (×100) and high (×400)
magniﬁcation. As shown in Figure 3, there was no clear
morphological diﬀerences between parental and D3H2LN-
AT2 cells, indicating that overexpression of AT2 receptors in
D3H2LN breast cancer cells does not signiﬁcantly alter cell
structure, shape, or organization.
We next evaluated whether the ectopically expressed
Flag-hAT2 receptor was localized at the cell surface of
D3H2LN-AT2 and able to bind AngII with high aﬃnity. To
address these questions, competition binding experiments
were performed on intact cells with tritium labeled AngII
(3H-AngII) in the presence of increasing concentrations of
unlabelled AngII. Results revealed a classical competition
binding proﬁle in D3H2LN-AT2 cells (Figure 4(a)), indicat-
ing the presence of a single population of receptors with
an IC50 of 1.55 ± 0.45nM (n = 3) for AngII, as expected
for a bona ﬁde AngII receptor. In contrast, no speciﬁc
AngII binding could be detected by binding assay in parental
D3H2LN cells (data not shown), indicating that parental
D3H2LN cells do not express detectable levels of AT1 and
AT2 receptors in our experimental conditions.
As shown in Figure 4(b), total binding of 4pM radiola-
belled AngII to D3H2LN-AT2 cells could be displaced (75%)
by adding an excess (1μM) of the selective AT2 receptor
antagonist PD123319 but not in the presence of an excess of
the AT1 receptor antagonist losartan. These results indicate
that AT2 is the major AngII binding site in D3H2LN-AT2
cells. They also suggest that overexpression of AT2 in breast
cancer cells does not modulate levels of membrane AT1
receptors. Thus, ectopically expressed Flag-hAT2 receptors
in D3H2LN breast cancer cells are correctly folded at the
plasma membrane and are able to bind the natural agonist
with the expected high aﬃnity. Total receptor density at the
cell surface was quantiﬁed to 65pmol of receptor per 105
D3H2LN-AT2 cells, which corresponds to a high level of
receptors.
In conclusion, we report here the generation and char-
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Figure 4: Binding studies. (a) Competition binding proﬁle for
AngII in D3H2LN-AT2 cells. Data are expressed as percentages
of the maximum speciﬁc binding of the radioligand 3H-AngII.
(b) Maximum binding obtained in the presence of the AT1
receptor antagonist (Losartan 10
−6 M) or AT2 receptor antagonist
(PD123319 10
−6 M), as compared to the control (vehicle). Values
are means ± SE of three independent experiments done in
duplicate.
cancer cells (D3H2LN-AT2) that express high amounts of
Flag-tagged human AT2 receptor at the plasma membrane.
These cells also express GFP and luciferase, which makes
them suitable for ﬂuorescence and bioluminescence studies
in vitro and in vivo. Of interest, D3H2LN-AT2 cells do not
express detectable AT1 binding sites, as evaluated by radioli-
gandbindingassay,thereforeallowingthecharacterizationof
AT2functionsindependentlyofthoserelatedtoAT1receptor
activation, which is of great interest in the context of AT1
blockade by ARBs.
Breast cancer is a leading cause of death by malignancy
in women worldwide, and identifying new personalized
therapeutic targets to ﬁght this disease is a challenge for the
coming years. Angiotensin receptors, being exposed at the
plasma membrane, are easily targetable by selective receptor
agonists or antagonists that may represent new and potent
anticancer drugs. With the emergence of novel nonpeptidicInternational Journal of Peptides 5
selective agonists of the AT2 receptor such as compound
21 [34, 35], reliable tools are now available to evaluate
the eﬀects of this receptor in vitro and in vivo.T h e r ei s
urgent need to determine the eﬀects of the AT2 receptor
subtype in breast cancer. The cellular model presented here
oﬀers a unique opportunity to evaluate the consequences
of AT2 receptor activation and blockade on breast cancer
proliferation, invasion, and migration, as well as on tumor
growth and metastasis formation.
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